Heparanase: Roles in cell survival, extracellular matrix remodelling and the development of kidney disease

Nature Reviews Nephrology

Volumn 13, Issue 4, 2017, Pages 201-212

  Rabelink, Ton J ^a   Van Den Berg, Bernard M ^a   Garsen, Marjolein ^b   Wang, Ganqi ^a   Elkin, Michael ^c   Van Der Vlag, Johan ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBIN III; BETA GLUCURONIDASE; CANCER GROWTH FACTOR; CATHEPSIN L; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYNAMIN; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR 2; HEPARANASE; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PROTEIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SYNAPTOPODIN; TOLL LIKE RECEPTOR; VASCULOTROPIN; VITAMIN D;

ALBUMINURIA; CELL COMMUNICATION; CELL CYCLE; CELL METABOLISM; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SYNTHESIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROSIS; GLOMERULONEPHRITIS; HUMAN; INFLAMMATION; KIDNEY DISEASE; METASTASIS; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; ANIMAL; ENZYMOLOGY; KIDNEY DISEASES; PHYSIOLOGY;

ANIMALS; CELL SURVIVAL; EXTRACELLULAR MATRIX; GLUCURONIDASE; HUMANS; KIDNEY DISEASES;

EID: 85011591327     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2017.6     Document Type: Review

References (139)

1. Dane, M. J. et al. A microscopic view on the renal endothelial glycocalyx. Am. J. Physiol. Renal Physiol. 308, F956-F966 (2015)
2. Sarrazin, S., Lamanna, W. C. &Esko, J. D. Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol. 3, a004952 (2011)
3. Bishop, J. R., Schuksz, M. &Esko, J. D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1037 (2007)
4. Esko, J. D. &Selleck, S. B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71, 435-471 (2002)
5. Taylor, K. R. &Gallo, R. L. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 20, 9-22 (2006)
6. Bartlett, C. S., Jeansson, M. &Quaggin, S. E. Vascular growth factors and glomerular disease. Annu. Rev. Physiol. 78, 437-461 (2016)
7. Raats, C. J. et al. Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. Am. J. Pathol. 156, 1749-1765 (2000)
8. Scott, R. P. &Quaggin, S. E. Review series: the cell biology of renal filtration. J. Cell Biol. 209, 199-210 (2015)
9. Wilson, J. C., Laloo, A. E., Singh, S. &Ferro, V. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase. Biochem. Biophys. Res. Commun. 443, 185-188 (2014)
10. Okada, Y. et al. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J. Biol. Chem. 277, 42488-42495 (2002)
11. Pikas, D. S., Li, J. P., Vlodavsky, I. &Lindahl, U. Substrate specificity of heparanases from human hepatoma and platelets. J. Biol. Chem. 273, 18770-18777 (1998)
12. Peterson, S. B. &Liu, J. Multi-faceted substrate specificity of heparanase. Matrix Biol. 32, 223-227 (2013)
13. Wu, L., Viola, C. M., Brzozowski, A. M. &Davies, G. J. Structural characterization of human heparanase reveals insights into substrate recognition. Nat. Struct. Mol. Biol. 22, 1016-1022 (2015)
14. Gandhi, N. S., Freeman, C., Parish, C. R. &Mancera, R. L. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-beta D glucuronidase (heparanase). Glycobiology 22, 35-55 (2012)
15. Vlodavsky, I. et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5, 793-802 (1999)
16. Gingis-Velitski, S. et al. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J. Biol. Chem. 279, 44084-44092 (2004)
17. Levy-Adam, F. et al. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J. Biol. Chem. 285, 28010-28019 (2010)
18. Shteper, P. J. et al. Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 22, 7737-7749 (2003)
19. Ogishima, T. et al. Increased heparanase expression is caused by promoter hypomethylation and up regulation of transcriptional factor early growth response 1 in human prostate cancer. Clin. Cancer Res. 11, 1028-1036 (2005)
20. Ogishima, T. et al. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene 24, 6765-6772 (2005)
21. Ateeq, B., Unterberger, A., Szyf, M. &Rabbani, S. A. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10, 266-278 (2008)
22. Baraz, L., Haupt, Y., Elkin, M., Peretz, T. &Vlodavsky, I. Tumor suppressor p53 regulates heparanase gene expression. Oncogene 25, 3939-3947 (2006)
23. Chen, G. et al. Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 43, 4971-4977 (2004)
24. Edovitsky, E. et al. Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107, 3609-3616 (2006)
25. Lerner, I. et al. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J. Clin. Invest. 121, 1709-1721 (2011)
26. Mestre, A. M. et al. Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J. Biol. Chem. 280, 35136-35147 (2005)
27. Mestre, A. M., Khachigian, L. M., Santiago, F. S., Staykova, M. A. &Hulett, M. D. Regulation of inducible heparanase gene transcription in activated T cells by early growth response. J. Biol. Chem. 278, 50377-50385 (2003)
28. Elkin, M. et al. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res. 63, 8821-8826 (2003)
29. Xu, X. et al. Estradiol induces heparanase 1 expression and heparan sulphate proteoglycan degradation in human endometrium. Hum. Reprod. 22, 927-937 (2007)
30. Rao, G. et al. Reactive oxygen species mediate high glucose-induced heparanase 1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis. Diabetologia 54, 1527-1538 (2011)
31. Kramer, A. et al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J. Am. Soc. Nephrol. 17, 2513-2520 (2006)
32. van den Hoven, M. J. et al. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol. Dial. Transplant. 24, 2637-2645 (2009)
33. Garsen, M. et al. Endothelin 1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx. J. Am. Soc. Nephrol. 27, 3545-3551 (2016)
34. Jiang, P. et al. Cloning and characterization of the human heparanase 1 (HPR1) gene promoter: role of GA binding protein and Sp1 in regulating HPR1 basal promoter activity. J. Biol. Chem. 277, 8989-8998 (2002)
35. Lu, W. C., Liu, Y. N., Kang, B. B. &Chen, J. H. Trans-activation of heparanase promoter by ETS transcription factors. Oncogene 22, 919-923 (2003)
36. Rao, G. et al. Induction of heparanase 1 expression by mutant B Raf kinase: role of GA binding protein in heparanase 1 promoter activation. Neoplasia 12, 946-956 (2010)
37. Garsen, M. et al. Endothelial nitric oxide synthase prevents heparanase induction and the development of proteinuria. PLoS ONE 11, e0160894 (2016)
38. Garsen, M. et al. Vitamin D attenuates proteinuria by inhibition of heparanase expression in the podocyte. J. Pathol. 237, 472-481 (2015)
39. Zetser, A. et al. Processing and activation of latent heparanase occurs in lysosomes. J. Cell Sci. 117, 2249-2258 (2004)
40. Levy-Adam, F. et al. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J. Biol. Chem. 280, 20457-20466 (2005)
41. Wood, R. J. &Hulett, M. D. Cell surface-expressed cation-independent mannose 6 phosphate receptor (CD222) binds enzymatically active heparanase independently of mannose 6 phosphate to promote extracellular matrix degradation. J. Biol. Chem. 283, 4165-4176 (2008)
42. Vreys, V. et al. Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6 phosphate receptors, and heparan sulfate proteoglycans. J. Biol. Chem. 280, 33141-33148 (2005)
43. Shteingauz, A., Ilan, N. &Vlodavsky, I. Processing of heparanase is mediated by syndecan 1 cytoplasmic domain and involves syntenin and alpha-actinin. Cell. Mol. Life Sci. 71, 4457-4470 (2014)
44. Yanagishita, M. &Hascall, V. C. Cell surface heparan sulfate proteoglycans. J. Biol. Chem. 267, 9451-9454 (1992)
45. Simeonovic, C. J. et al. Heparanase and autoimmune diabetes. Front. Immunol. 4, 471 (2013)
46. Massena, S. et al. A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 116, 1924-1931 (2010)
47. Escobar Galvis, M. L. et al. Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat. Chem. Biol. 3, 773-778 (2007)
48. Roucourt, B., Meeussen, S., Bao, J., Zimmermann, P. &David, G. Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Res. 25, 412-428 (2015)
49. Lenoir, O., Tharaux, P. L. &Huber, T. B. Autophagy in kidney disease and aging: lessons from rodent models. Kidney Int. 90, 950-964 (2016)
50. Ning, L. et al. Perlecan inhibits autophagy to maintain muscle homeostasis in mouse soleus muscle. Matrix Biol. 48, 26-35 (2015)
51. Shteingauz, A. et al. Heparanase enhances tumor growth and chemoresistance by promoting autophagy. Cancer Res. 75, 3946-3957 (2015)
52. Stewart, M. D. &Sanderson, R. D. Heparan sulfate in the nucleus and its control of cellular functions. Matrix Biol. 35, 56-59 (2014)
53. Stewart, M. D., Ramani, V. C. &Sanderson, R. D. Shed syndecan 1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk. J. Biol. Chem. 290, 941-949 (2015)
54. Smith, P. N. et al. Heparanase in primary human osteoblasts. J. Orthop. Res. 28, 1315-1322 (2010)
55. Wang, F. et al. Fatty acid-induced nuclear translocation of heparanase uncouples glucose metabolism in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 32, 406-414 (2012)
56. Buczek-Thomas, J. A., Hsia, E., Rich, C. B., Foster, J. A. &Nugent, M. A. Inhibition of histone acetyltransferase by glycosaminoglycans. J. Cell. Biochem. 105, 108-120 (2008)
57. Purushothaman, A. et al. Heparanase-mediated loss of nuclear syndecan 1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J. Biol. Chem. 286, 30377-30383 (2011)
58. Nobuhisa, T. et al. Translocation of heparanase into nucleus results in cell differentiation. Cancer Sci. 98, 535-540 (2007)
59. Sasaki, N., Higashi, N., Taka, T., Nakajima, M. &Irimura, T. Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate. J. Immunol. 172, 3830-3835 (2004)
60. Levidiotis, V., Freeman, C., Tikellis, C., Cooper, M. E. &Power, D. A. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J. Am. Soc. Nephrol. 15, 68-78 (2004)
61. Levidiotis, V., Kanellis, J., Ierino, F. L. &Power, D. A. Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int. 60, 1287-1296 (2001)
62. Levidiotis, V. et al. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J. Am. Soc. Nephrol. 15, 2882-2892 (2004)
63. van den Born, J. et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int. 43, 454-463 (1993)
64. van den Hoven, M. J. et al. Heparanase in glomerular diseases. Kidney Int. 72, 543-548 (2007)
65. Parish, C. R. The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 6, 633-643 (2006)
66. Rops, A. L. et al. Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int. 65, 768-785 (2004)
67. Lever, R., Rose, M. J., McKenzie, E. A. &Page, C. P. Heparanase induces inflammatory cell recruitment in vivo by promoting adhesion to vascular endothelium. Am. J. Physiol. Cell Physiol. 306, C1184-C1190 (2014)
68. Gilat, D. et al. Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH. J. Exp. Med. 181, 1929-1934 (1995)
69. Garsen, M. et al. Heparanase is essential for the development of acute experimental glomerulonephritis. Am. J. Pathol. 186, 805-815 (2016)
70. Gil, N. et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 61, 208-216 (2012)
71. Smith, R. J. et al. New approaches to the treatment of dense deposit disease. J. Am. Soc. Nephrol. 18, 2447-2456 (2007)
72. Rops, A. L. et al. Expression of glomerular heparan sulphate domains in murine and human lupus nephritis. Nephrol. Dial. Transplant. 22, 1891-1902 (2007)
73. Shafat, I., Ilan, N., Zoabi, S., Vlodavsky, I. &Nakhoul, F. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS ONE 6, e17312 (2011)
74. Shafat, I. et al. Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS ONE 7, e44076 (2012)
75. Ziolkowski, A. F., Popp, S. K., Freeman, C., Parish, C. R. &Simeonovic, C. J. Heparan sulfate and heparanase play key roles in mouse beta cell survival and autoimmune diabetes. J. Clin. Invest. 122, 132-141 (2012)
76. Bitan, M. et al. Heparanase prevents the development of type 1 diabetes in non-obese diabetic mice by regulating T cell activation and cytokines production. Diabetes Metab. Res. Rev. 24, 413-421 (2008)
77. Katz, A. et al. Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr. Med. Assoc. J. 4, 996-1002 (2002)
78. Maxhimer, J. B. et al. Heparanase 1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 54, 2172-2178 (2005)
79. Shafat, I. et al. An ELISA method for the detection and quantification of human heparanase. Biochem. Biophys. Res. Commun. 341, 958-963 (2006)
80. van den Hoven, M. J. et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 70, 2100-2108 (2006)
81. Wijnhoven, T. J. et al. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia 51, 372-382 (2008)
82. El-Asrar, A. M. et al. Upregulated expression of heparanase in the vitreous of patients with proliferative diabetic retinopathy originates from activated endothelial cells and leukocytes. Invest. Ophthalmol. Vis. Sci. 56, 8239-8247 (2015)
83. Boels, M. G. et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. Diabetes 65, 2429-2439 (2016)
84. Tashiro, K. et al. Urinary levels of monocyte chemoattractant protein 1 (MCP 1) and interleukin 8 (IL 8), and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 16, 1-4 (2002)
85. Thomas-Ijpelaar, D. et al. Modification of renal macrophage signaling via MCP 1 inhibition reduces albuminuria in diabetic nephropathy in mice [abstract iTH PO434]. J. Am. Soc. Nephrol. 27, 192A (2016)
86. Goldberg, R. et al. Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy. Diabetes 63, 4302-4313 (2014)
87. Yaddanapudi, S. et al. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J. Clin. Invest. 121, 3965-3980 (2011)
88. Asanuma, K., Shirato, I., Ishidoh, K., Kominami, E. &Tomino, Y. Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int. 62, 822-831 (2002)
89. Garsen, M. et al. Cathepsin L is crucial for the development of early experimental diabetic nephropathy. Kidney Int. 90, 1012-1022 (2016)
90. Nakagawa, T., Kosugi, T., Haneda, M., Rivard, C. J. &Long, D. A. Abnormal angiogenesis in diabetic nephropathy. Diabetes 58, 1471-1478 (2009)
91. Vlodavsky, I. &Friedmann, Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108, 341-347 (2001)
92. Meirovitz, A. et al. Heparanase in inflammation and inflammation-associated cancer. FEBS J. 280, 2307-2319 (2013)
93. Zetser, A. et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 66, 1455-1463 (2006)
94. Fantin, A. et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 116, 829-840 (2010)
95. Rops, A. L. et al. Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. Nephrol. Dial. Transplant. 27, 2853-2861 (2012)
96. Lygizos, M. I. et al. Heparanase mediates renal dysfunction during early sepsis in mice. Physiol. Rep. 1, e00153 (2013)
97. Grande, M. T. et al. Snail1 induced partial epithelial-to mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat. Med. 21, 989-997 (2015)
98. Lovisa, S. et al. Epithelial-to mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat. Med. 21, 998-1009 (2015)
99. Masola, V. et al. Heparanase: a potential new factor involved in the renal epithelial mesenchymal transition (EMT) induced by ischemia/reperfusion (I/R) injury. PLoS ONE 11, e0160074 (2016)
100. Masola, V. et al. Heparanase and syndecan 1 interplay orchestrates fibroblast growth factor 2 induced epithelial-mesenchymal transition in renal tubular cells. J. Biol. Chem. 287, 1478-1488 (2012)
101. Xu, D. &Esko, J. D. Demystifying heparan sulfate-protein interactions. Annu. Rev. Biochem. 83, 129-157 (2014)
102. Goodall, K. J., Poon, I. K., Phipps, S. &Hulett, M. D. Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR 4. PLoS ONE 9, e109596 (2014)
103. Blich, M. et al. Macrophage activation by heparanase is mediated by TLR 2 and TLR 4 and associates with plaque progression. Arterioscler. Thromb. Vasc. Biol. 33, e56-e65 (2013)
104. Brennan, T. V. et al. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood 120, 2899-2908 (2012)
105. Ritchie, J. P. et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan 1 axis. Clin. Cancer Res. 17, 1382-1393 (2011)
106. Nadanaka, S., Purunomo, E., Takeda, N., Tamura, J. &Kitagawa, H. Heparan sulfate containing unsubstituted glucosamine residues: biosynthesis and heparanase-inhibitory activity. J. Biol. Chem. 289, 15231-15243 (2014)
107. Hammond, E., Handley, P., Dredge, K. &Bytheway, I. Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues. FEBS Open Bio 3, 346-351 (2013)
108. Niu, T. T., Zhang, D. S., Chen, H. M. &Yan, X. J. Modulation of the binding of basic fibroblast growth factor and heparanase activity by purified lambda-carrageenan oligosaccharides. Carbohydr. Polym. 125, 76-84 (2015)
109. Gomes, C. L. et al. The protective role of fucosylated chondroitin sulfate, a distinct glycosaminoglycan, in a murine model of streptozotocin-induced diabetic nephropathy. PLoS ONE 9, e106929 (2014)
110. Myrup, B. et al. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345, 421-422 (1995)
111. van der Pijl, J. W. et al. Danaparoid sodium lowers proteinuria in diabetic nephropathy. J. Am. Soc. Nephrol. 8, 456-462 (1997)
112. Tamsma, J. T., van der Woude, F. J. &Lemkes, H. H. Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrol. Dial. Transplant. 11, 182-185 (1996)
113. Poplawska, A., Szelachowska, M., Topolska, J., Wysocka-Solowie, B. &Kinalska, I. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro-or macroalbuminuria. Diabetes Res. Clin. Pract. 38, 109-114 (1997)
114. Broekhuizen, L. N. et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 53, 2646-2655 (2010)
115. Lewis, E. J. et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am. J. Kidney Dis. 58, 729-736 (2011)
116. Packham, D. K. et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 23, 123-130 (2012)
117. Gambaro, G. et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J. Am. Soc. Nephrol. 13, 1615-1625 (2002)
118. Bang, K. et al. Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy. Yonsei Med. J. 52, 588-594 (2011)
119. Weissmann, M. et al. Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proc. Natl Acad. Sci. USA 113, 704-709 (2016)
120. Maione, A. et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol. Dial. Transplant. 26, 2827-2847 (2011)
121. Zeeuw, D. et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376, 1543-1551 (2010)
122. Agarwal, R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin. J. Am. Soc. Nephrol. 4, 1523-1528 (2009)
123. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01858532 (2016)
124. Zeeuw, D. et al. The effect of CCR2 inhibitor CCX140 B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol. 3, 687-696 (2015)
125. Menne, J. et al. C C motif-ligand 2 inhibition with emapticap pegol (NOX E36) in type 2 diabetic patients with albuminuria. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfv459 (2016)
126. Baricos, W. H. et al. Evidence suggesting a role for cathepsin L in an experimental model of glomerulonephritis. Arch. Biochem. Biophys. 288, 468-472 (1991)
127. Baricos, W. H., O'Connor, S. E., Cortez, S. L., Wu, L. T. &Shah, S. V. The cysteine proteinase inhibitor, E-64, reduces proteinuria in an experimental model of glomerulonephritis. Biochem. Biophys. Res. Commun. 155, 1318-1323 (1988)
128. Esko, J. D. &Lindahl, U. Molecular diversity of heparan sulfate. J. Clin. Invest. 108, 169-173 (2001)
129. Wang, L., Brown, J. R., Varki, A. &Esko, J. D. Heparin's anti-inflammatory effects require glucosamine 6 O sulfation and are mediated by blockade of L? and P selectins. J. Clin. Invest. 110, 127-136 (2002)
130. Ferreras, C. et al. Endothelial heparan sulfate 6 O sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor. J. Biol. Chem. 287, 36132-36146 (2012)
131. Lindahl, U., Backstrom, G., Thunberg, L. &Leder, I. G. Evidence for a 3 O sulfated D glucosamine residue in the antithrombin-binding sequence of heparin. Proc. Natl Acad. Sci. USA 77, 6551-6555 (1980)
132. Edge, A. S. &Spiro, R. G. Characterization of novel sequences containing 3 O sulfated glucosamine in glomerular basement membrane heparan sulfate and localization of sulfated disaccharides to a peripheral domain. J. Biol. Chem. 265, 15874-15881 (1990)
133. Edge, A. S. &Spiro, R. G. A specific structural alteration in the heparan sulphate of human glomerular basement membrane in diabetes. Diabetologia 43, 1056-1059 (2000)
134. Carter, N. M., Ali, S. &Kirby, J. A. Endothelial inflammation: the role of differential expression of N deacetylase/N sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. J. Cell Sci. 116, 3591-3600 (2003)
135. Rops, A. L. W. M. et al. Modulation of heparan sulfate in the glomerular endothelial glycocalyx decreases leukocyte influx during experimental glomerulonephritis. Kidney Int. 86, 932-942 (2014)
136. Endlich, K., Kriz, W. &Witzgall, R. Update in podocyte biology. Curr. Opin. Nephrol. Hypertens. 10, 331-340 (2001)
137. Rabelink, T. J. &de Zeeuw, D. The glycocalyx-linking albuminuria with renal and cardiovascular disease. Nat. Rev. Nephrol. 11, 667-676 (2015)
138. Buelli, S. et al. Beta-arrestin 1 drives endothelin 1 mediated podocyte activation and sustains renal injury. J. Am. Soc. Nephrol. 25, 523-533 (2014)
139. Mundel, P. &Reiser, J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int. 77, 571-580 (2010)